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Abstract
Background: Apolipoprotein B (APOB) is an integral part of the LDL, VLDL, IDL, Lp(a) and
chylomicron lipoprotein particles. The APOB pre-mRNA consists of 29 constitutively-spliced exons.
APOB exists as two natural isoforms: the full-length APOB100 isoform, assembled into LDL, VLDL,
IDL and Lp(a) and secreted by the liver in humans; and the C-terminally truncated APOB48,
assembled into chylomicrons and secreted by the intestine in humans. Down-regulation of
APOB100 is a potential therapy to lower circulating LDL and cholesterol levels.
Results: We investigated the ability of 2'O-methyl RNA antisense oligonucleotides (ASOs) to
induce the skipping of exon 27 in endogenous APOB mRNA in HepG2 cells. These ASOs are
directed towards the 5' and 3' splice-sites of exon 27, the branch-point sequence (BPS) of intron
26–27 and several predicted exonic splicing enhancers within exon 27. ASOs targeting either the
5' or 3' splice-site, in combination with the BPS, are the most effective. The splicing of other
alternatively spliced genes are not influenced by these ASOs, suggesting that the effects seen are
not due to non-specific changes in alternative splicing. The skip 27 mRNA is translated into a
truncated isoform, APOB87SKIP27.
Conclusion: The induction of APOB87SKIP27 expression in vivo should lead to decreased LDL and
cholesterol levels, by analogy to patients with hypobetalipoproteinemia. As intestinal APOB mRNA
editing and APOB48 expression rely on sequences within exon 26, exon 27 skipping should not
affect APOB48 expression unlike other methods of down-regulating APOB100 expression which
also down-regulate APOB48.
Background
Apolipoprotein B (APOB – OMIM 107730) is the princi-
pal structural apolipoprotein in the LDL, VLDL, IDL,
Lp(a) and chylomicron lipoprotein particles [1]. The
APOB pre-mRNA comprises 29 exons, all constitutively
spliced into the mature mRNA. There exist two natural
protein isoforms, the full-length APOB100 and the C-ter-
minal truncation APOB48. APOB100 is synthesized in the
liver, and this isoform is required for the assembly of
VLDL, IDL, LDL, and Lp(a). Along with APOE, APOB100
is the ligand for the LDL receptor. Excess levels of the
APOB100-containing particles LDL and Lp(a) have been
implicated in atherogenesis [2]. APOB48 is generated by
tissue-specific RNA editing of a CAA codon to a premature
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to the N-terminal 48% of APOB100. Editing is performed
by a protein complex known as the editosome, which
consists of the catalytic subunit APOBEC-1 and accessory
factors. The RNA editing site and mooring sequence nec-
essary for editosome binding and function are within
exon 26. The APOB48 isoform is required for chylomi-
cron assembly and intestinal fat transport. As the APOB48
isoform lacks the C-terminal domain necessary for LDL
receptor binding, chylomicrons are unable to bind via this
receptor, and are cleared by interaction of APOE with the
chylomicron remnant receptor [3].
Because of its central role in atherosclerosis, APOB has
become a major therapeutic target. Down-regulation of
APOB100 expression would be expected to decrease
VLDL, IDL, LDL and Lp(a) levels, and therefore prevent
the development of atherosclerosis. Over-expression of
the rabbit APOBEC-1 enzyme in transgenic mouse livers
has been shown to cause increased RNA editing, isoform
switching from APOB100 to APOB48, and lowered LDL
levels [4]. Other approaches have concentrated on the
down-regulation of APOB mRNA levels, for example by
chimeric antisense-oligonucleotide mediated RNase H
degradation [5], and by RNA interference [6,7].
We hypothesized that modifying APOB splicing would
cause the expression of an alternative isoform of APOB.
We selected exon 27 as our target for three reasons. Firstly,
translation of the APOB mRNA lacking exon 27 (skip 27
mRNA) would generate a C-terminally truncated isoform
of APOB, APOB87SKIP27, which is similar to the C-termi-
nal truncations seen in some patients with hypobetalipo-
proteinemia. Heterozygotes for these mutant alleles of
APOB have lower cholesterol and LDL levels [8]. Sec-
ondly, the 5' splice-site of exon 27, when scored for its
similarity to the splice-site consensus using the Shapiro
and Senapathy position weight matrix, was the weakest of
all the 5' splice-sites of the internal exons of APOB at
60.73 [9]. We reasoned that as constitutive 5' splice-sites
in general score better than alternatively spliced 5' splice-
sites [10], APOB exon 27 would be the most amenable to
alternative splicing. Thirdly, as the sequences necessary for
RNA editing are present in exon 26, the skip 27 mRNA
should be edited as usual in the intestine, and APOB48
expression should be unaffected.
We demonstrate in this paper that the induction of exon
27 skipping causes the expression and secretion of a trun-
cated isoform of APOB which is potentially of therapeutic
utility in lowering LDL and cholesterol levels in vivo.
Results
ASO targeted to the splice-sites of APOB exon 27 induce 
exon skipping
In order to modify exon 27 splicing, we used splice-site
ASOs, which have previously been used to modify splic-
ing in the dystrophin gene [11-13] and to correct the aber-
rant alternative splicing in the ß-thalassemia mutation
IVS2-654 [14]. 2'O-methyl RNA ASOs were targeted to the
5' and 3' splice-sites of exon 27, as well as the branch-
point sequence (BPS) just adjacent to the 3' splice-site of
intron 26–27, to block their recognition by the spliceo-
some. The design of the ASOs is shown in Fig. 1. These
ASOs were transfected into HepG2 cells, and total RNA
was extracted and analyzed by RT-PCR with primers com-
plementary to regions within exons 26 and 28.
As shown in Fig. 2, mock-transfected cells (no oligo)
showed no skipping of exon 27, consistent with this being
a constitutively-spliced exon. Cells transfected with an
unrelated ASO directed against the firefly luciferase gene
(Fluc A1) did not show any skipping of exon 27. Surpris-
ingly, the ASOs directed either to the 5' or to the 3' splice-
site (skip 27-5 and skip 27-3 respectively) did not have
any effect on splicing. However, when both 5' and 3'
splice-sites were targeted by the same ASO (skip 27–53), a
shorter RT-PCR product was obtained. This effect was
stronger if either skip 27-5 or skip 27-3 was linked to a
sequence targeting the BPS (skip 27-5B and skip 27-3B
respectively). Cloning and sequencing confirmed that this
shorter RT-PCR product consists of exon 26 sequence
spliced to exon 28, and therefore corresponds to the skip
27 mRNA. An ASO targeting the BPS alone (skip 27-B)
was not effective in inducing skipping (data not shown).
Moreover, a mixture of either skip 27-5 or skip 27-3 with
skip 27-B did not induce skipping, indicating that these
ASOs do not act synergistically (data not shown).
We also tested ASOs tailed with an RNA sequence
designed to bind the inhibitory splicing factor hnRNP A1,
a strategy that was previously shown to increase the effi-
ciency of alternative splicing in the Bcl-x pre-mRNA in vivo
[15,16]. The Fluc A1 ASO, which bears the A1 tail, does
not have any effect on exon 27 skipping, as noted above.
Linking the skip 27–53 ASO with the A1 tail (skip 27–53
A1) appeared to decrease the skipping of exon 27 com-
pared to skip 27–53 itself (Fig. 2). Mutation of the A1 tail
such that it does not bind hnRNP A1 (skip 27–53 mut A1)
restored its effects to some extent, suggesting that hnRNP
A1 itself is interfering with the ability of the skip 27–53
ASO to induce skipping.
Fig. 3 shows that at concentrations ranging between 0–
250 nM, the skip 27-3B ASO was consistently the most
effective at inducing exon 27 skipping. A scramble muta-
tion of skip 27-3B, skip 27-3B scram, had no effect even atPage 2 of 13
(page number not for citation purposes)
BMC Molecular Biology 2007, 8:3 http://www.biomedcentral.com/1471-2199/8/3the highest concentration, indicating that the alternative
splicing effect of the skip 27-3B ASO is sequence-specific.
Fluorescence microscopy of cells transfected with 5' fluo-
rescein-labelled skip 27-3B and skip 27-3B scram ASOs
showed that both ASOs were transfected with equal effi-
ciency into ~80% cells, indicating that differences in trans-
fection efficiency were not responsible for the different
effects seen (data not shown). As before, tailing skip 27-
3B with the A1 tail significantly reduced the efficiency of
the ASO, as noted before with the skip 27–53 ASO. Muta-
tion of the A1 tail (skip 27-3B mut A1) restored the effi-
ciency of skipping to levels not significantly different from
skip 27-3B, again suggesting that hnRNP A1 specifically
interferes with the ability of the skip 27-3B ASO to induce
skipping.
We conclude, therefore, that the 5' splice-site, the 3' splice-
site, and the BPS are crucial for the constitutive inclusion
of exon 27. ASOs targeting single splice-sites are not effec-
tive in inducing exon 27 skipping. Instead, combination
ASOs that target two splice-sites are effective at inducing
exon 27 skipping, and an ASO targeting both the 3' splice-
site and the BPS (skip 27-3B) appears to be the most effec-
tive in doing so. As mixing individual single splice-site
ASOs, for example combining skip 27-3 with skip 27-B,
was not effective in inducing exon 27 skipping, it is
unlikely that these ASOs work by simple occupancy of
splice-sites and competition with splicing factors. Instead,
we speculate that these ASOs might operate by inducing
an alternative secondary structure in the APOB mRNA. An
mFold analysis of the predicted conformation of exon 27
and its flanking intronic sequences [17] shows that the
Design of skip 27 ASOsFigure 1
Design of skip 27 ASOs. The sequences of the intronic regions flanking exon 27 and parts of exon 27 are shown at the top 
– intronic sequences are in small letters, exonic sequences are in caps, exon 27 is enclosed in the grey-shaded box. The splice-
sites (BPS = branch-point sequence; 3'ss = 3' splice-site; 5'ss = 5' splice-site) are outlined with dotted lines. The Shapiro and 
Senapathy (S&S) scores below each splice-site reflect the degree of similarity of these sequences to the splice-site consensus 
[9]. The ASO design is indicated below. Arrows run in the 5' to 3' direction. Three classes of ASO tested are distinguished 
within each box: single splice site ASOs that target individual splice sites; combination splice-site ASOs that target two splice-
sites simultaneously; combination splice-site ASOs that target two splice-sites and are linked to an hnRNP A1 binding tail (A1 – 
the sequence of this tail is presented) or a mutated tail that is unable to bind hnRNP A1 (mut A1).
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open structures [see Additional file 1]. As the secondary
structure of RNA is known to influence splicing in some
instances [18], it is possible that binding of the skip 27-3B
ASO closes these open structures and discourages splice-
site recognition by the spliceosome. Consistent with this
idea, hnRNP A1 is known to unwind nucleic acid second-
ary structure [19], and this property may explain its para-
doxical ability to restore exon 27 inclusion, perhaps by
interfering with ASO hybridization to the APOB pre-
mRNA (Figs. 2 and 3).
ASOs targeted to putative exonic splicing enhancer motifs 
within exon 27 weakly induce its skipping
Exonic splicing enhancers (ESEs) are sequences within
exons that activate inclusion of the exon that harbors
them, typically by binding SR proteins [20]. We reasoned
that ESEs within exon 27 might contribute to the constitu-
tive inclusion of this exon, and that exon 27 skipping
might be induced by interfering with SR protein binding
to these elements. We turned to computational tools in
order to identify potential ESEs: ESEfinder [21], RESCUE-
ESE [22], and PESXs server [23,24]. Based on these predic-
tions, four ASOs targeting nucleotides 6–25, 31–50, 61–
80 and 88–107 were tested (Fig. 4a).
Fig. 4b shows that these ASOs induced skipping of exon
27, but much less efficiently than the splice-site ASOs
described above. Furthermore, in order to test the idea
that the exonic ASOs might synergize with each other, we
transfected HepG2 cells with mixtures of the exonic ASOs.
However, combinations of exonic ASO pairs and mixtures
of all four exonic ASOs, although demonstrating some
additive effects, were inefficient at inducing exon 27 skip-
ping: the maximum exon 27 skipping demonstrated with
mixtures of all four exonic ASOs was 1–2% (data not
shown). We conclude, therefore, that the identified ESEs
play a relatively small role in the inclusion of exon 27 dur-
ing splicing.
ASOs targeting the splice-sites of APOB exon 27 do not 
generally affect the splicing of other alternatively-spliced 
genes
Because splice-sites conform to a degenerate consensus,
there exists a possibility that the APOB skip 27 splice-site
ASOs might potentially bind to other pre-mRNA splice-
sites. We searched for matches to the exon 27 splice-sites
in a comprehensive database of splice-sites, SpliceRack
[25], but did not identify any extra matches in the human
database, indicating that this possibility is unlikely. In
order to directly test the hypothesis that the splice-site
ASOs might be non-specifically affecting alternative splic-
ing, for example by binding splicing factors or by hybrid-
izing to other pre-mRNAs, we tried to detect changes in
the well described alternative splicing of other exons such
as TSC2 exon 25, Caspase-9 exons 3,4,5 and 6, and insulin
receptor exon 11 [26-29]. As shown in Fig. 5 there was no
significant effect of skip 27 -53, -5B and -3B ASO transfec-
tion on the pattern of insulin receptor, TSC2, or Caspase-
9 alternative splicing, suggesting that the effects of our
ASOs on APOB exon 27 are not explained by a generalized
and non-specific alteration of alternative splicing.
The skip 27 mRNA is translated into a secreted 
polypeptide
The skip 27 mRNA encodes a truncated protein,
APOB87SKIP27, which contains the N-terminal 3929
Alternative splicing of exon 27 induced by APOB exon 27 splice-site ASOsFigure 2
Alternative splicing of exon 27 induced by APOB exon 
27 splice-site ASOs. (a) HepG2 cells were transfected with 
the indicated ASOs at 250 nM for 48 hours. RT-PCR was 
carried out on the total RNA extracted from these cells with 
oligonucleotides annealing to the adjacent exons 26 and 28. 
The -RT control PCR was performed without reverse tran-
scriptase. The positions of the bands corresponding to the 
APOB mRNA species with exon 27 (inc 27) and without exon 
27 (skip 27) are indicated on the right side. Fragment lengths 
in bp of pBR322-MspI markers are indicated on the left side. 
The band corresponding to skip 27 mRNA was cloned and 
sequenced to confirm that exon 26 is spliced to exon 28. (b) 
The graph shows the quantitative data from three independ-
ent replications of the experiment (error bars show the 
S.E.M.). Overall one-way repeated measures ANOVA p-value 
was < 0.0001, indicating statistically significant differences 
between groups. Dunnett's multiple comparison test was 
used to compare the no-oligo control versus ASO-trans-
fected cells: statistically significant differences were found 
with skip 27–53, skip 27-5B, and skip 27-3B.
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Dose titration of selected APOB skip 27 ASOsFigure 3
Dose titration of selected APOB skip 27 ASOs. (a) HepG2 cells were transfected with the indicated ASOs at increasing 
concentrations from 25 to 250 nM for 48 hours. RT-PCR was carried out on the total RNA extracted from these cells with oli-
gonucleotides annealing to the adjacent exons 26 and 28. The -RT control PCR was performed without reverse transcriptase. 
The positions of the bands corresponding to the APOB mRNA species with exon 27 (inc 27) and without exon 27 (skip 27) are 
indicated on the right side. Fragment lengths in bp of pBR322-MspI markers are indicated on the left side. (b) The graph shows 
the quantitative data from three independent replications of the experiment (error bars show the S.E.M.). The data was ana-
lyzed using a repeated measures two-way ANOVA, using Bonferroni's test to compare exon 27 skipping between skip 27-3B 
and the other ASOs at 250 nM: statistically significant differences are seen with skip 27–53, skip 27-3B scram and skip 27-3B 
A1. No statistically significant difference is seen with skip 27-5B and skip 27-3B mutA1.
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Effect of ASOs targeting APOB exon 27 sequencesFigure 4
Effect of ASOs targeting APOB exon 27 sequences. (a) ESEfinder output for APOB exon 27, using version 2.0 matrices 
and thresholds [21]. Y-axis shows ESEfinder above-threshold scores for identified matches; X-axis corresponds to the exon 27 
sequence. Red = SF2/ASF, blue = SC35, green = SRp40, yellow = SRp55. The light grey horizontal lines indicate the matches 
that were found by RESCUE-ESE [22]. The dark grey lines indicate the ESE candidates identified by PESXs server [23, 24]. 
ASOs were designed to bind to locations corresponding to ESE clusters, and these locations are represented below the X-axis 
by the arrows, which run from the 5' to 3' direction. (b) RT-PCR assay for exon 27 skipping with RNA from cells transfected 
with ASOs at 250 nM. Exonic ASOs 6–25, 31–50, 61–80, 88–107 weakly promote exon 27 skipping, whereas scrambled ver-
sions of these ASOs had no effect on exon 27 skipping. (c) Quantitative data from three independent experiments. Error bars 
show S.E.M. Overall repeated measures one-way ANOVA showed p < 0.0001, indicating significant differences between com-
pared groups. Dunnett's multiple comparison test showed a significant difference between skip 27-3B and 3B scram (p < 0.01), 
but no statistically significant differences were seen between skip 27-3B scram and other skip 27 ASOs.
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BMC Molecular Biology 2007, 8:3 http://www.biomedcentral.com/1471-2199/8/3amino acid residues of APOB100 along with a divergent
37 amino acid peptide at the C-terminus, ending at a pre-
mature termination codon within the exon 28 sequence.
Those mRNAs that harbor a premature termination codon
(PTC) more than 55–60 nt upstream of the last exon-exon
junction are subject to surveillance and down-regulation,
in a process known as nonsense-mediated decay (NMD -
[30]). The skip 27 mRNA's PTC is 71 nt upstream of the
exon 28–29 junction, and is a candidate for down-regula-
tion by NMD. We treated skip 27-3B ASO-transfected cells
with cycloheximide, which is known to inhibit NMD in
HepG2 cells [31,32]. Under these conditions we did not
see up-regulation of the skip 27 mRNA, indicating that
skip 27 mRNA appears not to be subject to down-regula-
tion by NMD [see Additional file 2]. Although this is
somewhat surprising, some potential substrates for NMD
appear to escape NMD [33,34] and it is possible that the
skip 27 mRNA contains a stabilizer element, similar in
function to that found in the PGK1 mRNA in yeast [35],
which allows it to escape NMD. In addition, the APOBEC-
1 complementation factor ACF [36], which is present
within HepG2 cells, is known to protect edited APOB
mRNA from NMD [37], and it is possible that this protec-
tion is extended to the skip 27 mRNA.
As the skip 27 mRNA is not subject to NMD, we consid-
ered the possibility that APOB87SKIP27 might be translated
from the skip 27 mRNA. In order to assess this, ASO-
treated HepG2 cells were labelled with 35S-methionine/
cysteine. The cell lysates and media were immunoprecipi-
tated with anti-APOB, subjected to SDS-PAGE and then to
autoradiography. Fig. 6 shows that the cells treated with
the skip 27-3B ASO expressed two isoforms: a long iso-
form corresponding to APOB100 and a short isoform con-
sistent with APOB87SKIP27. Both isoforms were recovered
from the cell lysates and from the culture medium. Nei-
ther the mock-transfected cells, nor the cells treated with
skip 27-3B scram expressed APOB87SKIP27.
Interestingly, the relative ratios of APOB100 and
APOB87SKIP27 differed between that found in the cell
lysate and that secreted into the medium. In the cell lysate,
there appears to be a predominance of APOB87SKIP27 over
APOB100. In the medium, there is a predominance of
APOB100 over APOB87SKIP27. This may be due to
decreased secretion of APOB87SKIP27 relative to APOB100,
causing an increased cellular retention of APOB87SKIP27
relative to APOB100. This is a finding that parallels the
decreased secretion rate of the APOB89 truncation in
APOB89 heterozygotes [38]. We conclude, therefore, that
the skip 27 mRNA is translated into the APOB87SKIP27 iso-
form and that this protein is secreted into the culture
medium along with APOB100.
APOB skip 27 ASOs have no effect on the alternative splicing of other exonsFigur  5
APOB skip 27 ASOs have no effect on the alternative 
splicing of other exons. (a) The indicated ASOs were 
transfected at 250 nM into HepG2 cells, and total RNA from 
these was analyzed by RT-PCR for inclusion/skipping of APOB 
exon 27; GAPDH, as loading control; inclusion/skipping of 
insulin receptor (INSR) exon 11; inclusion/skipping of TSC2 
exon 25; and inclusion/skipping of Caspase-9 exons 3–6. The 
identity of each band is listed below each set of 6 lanes from 
top band to bottom band: APOB inc 27 = exon 27 included; 
APOB skip 27 = exon 27 skipped, GAPDH = amplified region 
of GAPDH mRNA 7–261 nt; INSR B = exon 11 included, 
INSR A = exon 11 skipped; TSC2 +25 = exon 25 included, 
TSC2 -25 = exon 25 skipped; Caspase-9 isoform 9 = exons 
3–6 included, Caspase-9 isoform 9b = exons 3–6 skipped. 
Transfection of ASOs does not affect the alternative splicing 
of INSR, TSC2 and Caspase-9. (b) Quantitative data for alter-
native splicing of each gene from three independent repli-
cates. Error bars represent S.E.M. One-way repeated 
measures ANOVA of the APOB skip 27 dataset showed p = 
0.0007, representing significant statistical differences 
between groups: Dunnett's multiple comparison test showed 
statistically significant differences between the no-oligo con-
trol and skip 27–53, 5B and 3B, as indicated. One-way 
ANOVA p-values for the INSR, TSC2 and Caspase-9 datasets 
were 0.3716, 0.5887, and 0.1674 respectively, indicating no 
statistically significant differences between groups.
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Due to its role in the assembly of the atherogenic lipopro-
tein particles LDL and Lp(a), APOB has become a prime
target for therapeutic interventions to reduce LDL and
Lp(a) levels, and therefore perhaps to retard atherosclero-
sis. Approaches that have been used include over-expres-
sion of APOBEC-1 to induce RNA editing of APOB mRNA
and isoform switching to APOB48 [4], RNase H-mediated
degradation of APOB mRNA using ASOs [5], and RNA
interference with siRNA duplexes [6,7]. We demonstrate
in this paper that ASOs targeted to the splice-sites of APOB
exon 27 are effective in inducing alternative splicing of
exon 27, and that this skip 27 mRNA is translated to a
short isoform of APOB, APOB87SKIP27. We are conscious
that HepG2 cells, although they are able to synthesize and
secrete APOB, do not assemble normal VLDL or LDL [39].
However, the data presented suggests that it is in principle
feasible to induce the skipping of the normally constitu-
tive exon 27 in hepatocytes. Should further work demon-
strate that it is possible to do this in vivo with injected or
ingested ASOs, we speculate that this could potentially
form the basis of a therapy to reduce APOB100 expression
and to reduce circulating LDL and cholesterol levels.
Our work relies on 2'O-methyl RNA oligonucleotides as
splice-site ASOs, and joins a growing list of synthetic
nucleic acid-based compounds that have been used to
modify splicing [40]. ASOs employing a combination of
phosphorothioate and 2'O-methyl RNA modifications
have been used to modify dystrophin splicing [11,12], ß-
globin splicing [14], and SMN2 splicing [41]. Other
chemistries such as 2'O-methoxyethyl ASO [42], mor-
pholino ASO [43], peptide-nucleic acid (PNA) com-
pounds [44] and chimeric DNA/locked nucleic acid
oligonucleotides [45] represent alternatives that might, in
future work, be used to modify APOB exon 27 splicing.
We have also used PNA-peptide chimeras in an approach
termed ESSENCE (exon-specific splicing enhancement by
small chimeric effectors). These compounds comprise an
antisense sequence that targets the compound specifically
to a particular exon. The antisense sequence is linked to
RS dipeptide repeats which serve to activate splicing and
inclusion of the targeted exon. This approach has been
successfully used to modify the alternative splicing in the
SMN2 pre-mRNA [46] and the Bcl-x pre-mRNA [47]. The
final choice for the chemistry of a therapeutic compound
will depend crucially on several factors, including the effi-
cacy of APOB exon 27 skipping, the pharmacokinetics and
bioavailability, the efficiency of translocation across the
cell and nuclear membranes, and the safety of the com-
pound.
APOB87SKIP27 is predicted to consist of the N-terminal
3929 residues of APOB100. As there is a frameshift
induced by the skipping of exon 27, part of the exon 28
sequence is translated to a divergent 37 amino acid
sequence at the C-terminus. We postulate that this iso-
form, if assembled into VLDL and LDL, will have similar
properties to the C-terminally truncated isoforms that
have been described and characterized in kindreds with
natural mutations in APOB causing hypobetalipopro-
teinemia. One such mutant isoform, APOB89, is pro-
duced by a single nucleotide deletion in exon 29, and
lowers circulating cholesterol levels to the 5th percentile
[48,49]. Patients heterozygous for APOB89 synthesize
and secrete APOB89 at 92% of the rate of APOB100, but
LDL particles containing APOB89 show greater fractional
catabolic rates compared to those containing APOB100,
Transfection of APOB skip 27 ASOs causes expression of a short isoform of APOB, APOB87SKIP27Figur  6
Transfection of APOB skip 27 ASOs causes expression of a short isoform of APOB, APOB87SKIP27. HepG2 cells 
were transfected with the indicated ASOs at 250 nM, then pulse-labelled with Trans-35S-Label for 1 hour in the presence of 
oleic acid-BSA, which stimulates APOB100 expression [62]. Cell lysates or cell culture media were immunoprecipitated with a 
polyclonal antibody for APOB. The immunoprecipitates were subjected to SDS-PAGE (4% Tris-glycine), followed by autoradi-
ography. The gel shown is representative of three experiments. A short isoform of APOB, APOB87SKIP27, is seen with the skip 
27-3B ASO. This short isoform is not seen with the 3B scram ASO, nor with the no-oligo control. This matches the presence 
and absence of skip 27 mRNA seen with these ASOs.
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ing particles for the LDL receptor [38]. APOB89 also
appears to have a dominant negative effect on the secre-
tion rate of APOB100, reducing the production rate in
APOB89 heterozygotes to 30% compared to normal indi-
viduals [50]. The combination of these phenomena,
therefore, leads to a disproportionate decrease in LDL and
cholesterol levels in APOB89 heterozygotes. Deletion of
the C-terminal 10% of the protein renders APOB unable
to assemble into Lp(a) [51]. Consistent with this, in
APOB89 heterozygotes, APOB89 is not associated with
the Lp(a) particles in these patients. However, Lp(a) levels
are not decreased in these individuals. The circulating
Lp(a) particles contain APOB100 exclusively, and are
indistinguishable from normal Lp(a) in terms of size and
density [52].
Another mutant isoform seen in patients with familial
hypobetalipoproteinemia, APOB87Padova, is caused by a
single nucleotide deletion at the 5' end of exon 28, leading
to a shortened isoform comprising the N-terminal 3968
residues of APOB plus a divergent C-terminal 37 amino
acid sequence. This C-terminal sequence, which results
from the frameshift of exon 28 sequence introduced by
the deletion, is identical over 36/37 residues with the C-
terminal divergent sequence of APOB87SKIP27, as the same
frameshift is introduced by skipping exon 27. Conse-
quently, APOB87Padova is an isoform that is very similar to
APOB87SKIP27, the principal difference being that
APOB87Padovaincludes the APOB sequence coded by exon
27. As with APOB89, the APOB87Padova-containing LDL
from these patients exhibits an increased fractional cata-
bolic rate and decreased production compared to normal
individuals, leading to cholesterol levels about 2/3rd nor-
mal and LDL levels of about 50% normal in heterozygous
individuals [53]. If it were possible to partially induce
APOB87SKIP27 expression in vivo, this could cause a
decreased secretion rate of APOB100, and that
APOB87SKIP27-containing VLDL, IDL and LDL would be
cleared at a faster rate than normal, leading to decreased
levels of these particles. However, since these ASOs only
induce partial exon 27 skipping, APOB100 would still be
synthesized and assembled into Lp(a). Therefore, we
would also predict that this would not change Lp(a) lev-
els. We can foresee one theoretical problem with our ther-
apeutic approach. Should it be possible to induce
APOB87SKIP27 in vivo, the presence of the 37 amino acid
divergent sequence at the C-terminus could induce an
immune response to the novel epitope thus generated. It
is unknown at this time as to whether this immune
response might have any clinical consequences such as
antibody interference with APOB87SKIP27 function or an
autoimmune response.
A therapy based on APOB87SKIP27 induction may have
particular utility in patients with familial hypercholester-
olemia, such as those with familial defective APOB100
(FDB). This condition is due to point mutations that dis-
rupt the conformation of the LDL receptor-binding
domain of APOB, leading to decreased affinity for the
receptor, decreased clearance of VLDL/IDL/LDL particles,
hypercholesterolemia, and therefore an increased risk of
atherosclerotic disease [8]. The most common mutation,
R3500Q, appears to be quite prevalent in Western and
Central European populations, with a heterozygote prev-
alence of ~1/250 in Switzerland [54]. C-terminal dele-
tions of APOB restore the ability of FDB LDL particles to
bind to the LDL receptor [55,56]. We predict, therefore,
that induction of APOB87SKIP27 in patients with FDB
would be expected to restore the ability of APOB87SKIP27-
containing LDL to bind to its cognate receptor. Further-
more, we speculate that patients with familial hypercho-
lesterolemia due to LDL receptor mutations may benefit
from the induction of APOB87SKIP27 by increasing the
affinity of APO87-containing LDL for the LDL receptor.
The various methods that have so far been proposed for
down-regulating APOB100 expression have encountered
various side-effects, some of them of a serious nature. For
example, the over-expression of APOBEC-1 in mouse liv-
ers led to liver dysplasia and hepatocellular carcinomas, a
phenomenon that has been attributed to promiscuous
editing of mRNAs other than APOB [4]. Another problem
common to those therapeutic interventions that generally
down-regulate APOB mRNA levels is that they have the
potential to repress both APOB100 and APOB48 expres-
sion. In the case of RNA interference by cholesterol-conju-
gated siRNA, APOB48-containing chylomicron levels are
reduced by approximately 50% [6]. The ASO ISIS 147764,
when administered to mice, down-regulates the APOB
mRNA and causes a 90% reduction in circulating and liver
levels of both APOB100 and APOB48, although, interest-
ingly, no reduction in APOB48 protein levels is seen in the
intestine [5]. This reduction in APOB48 expression could
interfere with chylomicron assembly and potentially
cause fat malabsorption from the intestine, a serious side
effect. Induction of exon 27 skipping by ASOs, however,
might not be subject to this problem, as the RNA editing
site resides within exon 26. The skip 27 mRNA should
therefore be edited in the intestine, and translated to
result in APOB48. Consistent with this supposition,
patients with APOB89 familial hypobetalipoproteinemia
produce intestinal APOB48 as normal [57].
Conclusion
High circulating LDL and cholesterol levels are associated
with atherosclerosis, and therapeutic interventions to
reduce these levels have been shown to decrease the inci-
dence of the complications of atherosclerosis, such asPage 9 of 13
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as HmG CoA reductase inhibitors, there remains a
demand for other interventions to reduce LDL and choles-
terol levels. Using ASO-induced alternative splicing of
APOB mRNA, we have demonstrated that it is possible to
induce the expression of a novel isoform of APOB that
simulates hypobetalipoproteinemia, and which should
reduce circulating LDL and cholesterol levels. This repre-
sents a new and promising technique that may therefore
have applications in therapeutic modification of
APOB100 expression.
Methods
Cell culture and transfection of antisense oligonucleotides
2'O-methyl antisense oligonucleotides (ASOs – see Table
1) were ordered from Dharmacon (Lafayette, CO).
HepG2 cells were maintained in Minimum Essential
Medium with Earle's salts and glutamine, 10% fetal
bovine serum (Gibco/Invitrogen, Carlsbad, CA) at 37°C
under 5% CO2. ASOs were transfected in 12-well plates,
with 1 × 106 cells per well, using 2.4 μl Lipofectamine
2000 in 200 μl OptiMEM-I (Invitrogen) as per the manu-
facturer's protocol, then incubated for 48 hours before
harvesting. A time-course revealed that the ASO effects
were seen as early as 24 hours and lasted up to 72 hours.
No ASO effects were seen at 96 or 120 hours. The optimal
effects were seen at 48 hours. ASOs skip 27-3B and skip
27-3B scram were also labelled with fluorescein at the 5'
end and examined after transfection with a Nikon Eclipse
microscope with a FITC filter set to control for oligonucle-
otide transfection efficiency.
RNA isolation and RT-PCR
Total RNA was isolated from cells using the RNeasy Micro
kit (Qiagen, Valencia, CA). The RNA was quantified using
the QuantIt Ribogreen kit (Invitrogen), and 2.5 μg of total
RNA was reverse-transcribed using Transcriptor reverse
transcriptase (Roche Applied Science, Indianapolis, IN)
with an oligo dT15 primer as per the manufacturer's proto-
col. 0.25 μl of the cDNA was subjected to PCR with 200
μM of each oligonucleotide and FastStart Taq (Roche
Applied Science) using the following program: 95°C for
30 sec, 58°C for 30 sec, 72°C for 30 sec. 0.5 μCi of [α-32P]
dCTP (Perkin-Elmer, Wellesley, MA) was included per 10
μl reaction. Under these conditions, the number of cycles
was adjusted for each oligonucleotide pair to allow ampli-
fication to the exponential phase. The sequences of the
oligonucleotide pairs are given in Table 2. The PCR reac-
tion was then subjected to PAGE on a non-denaturing 8%
gel, dried and autoradiographed. Quantitation was car-
ried out using a Molecular Dynamics Typhoon Phos-
phorImager and ImageQuant software (GE Healthcare
Life Sciences, Piscataway, NJ). The quantified bands were
normalized according to the G+C content, and the per-
centage alternative splicing was calculated as isoform/
total of all isoforms. Statistical analysis and graphing was
carried out using Prism 4.0c software (GraphPad Soft-
ware, San Diego, CA).
Computational identification of exonic splicing enhancers
ESEfinder [21,58], RESCUE-ESE [22,59] and PESXs server
[23,24,60] were used to search the APOB exon 27
sequence for putative exonic splicing enhancers.
Table 1: Sequences of antisense oligonucleotides (ASOs) employed in the experiments
ASO name Sequence (5'-3') ACGU = 2'O-methyl RNA bases, acgu = RNA bases
skip 27-5 AUAAAAGCUCCAUACUGAAG
skip 27-3 CAAAACUGUAUAGGAGAGAU
skip 27–53 AUAAAAGCUCCAUACUGAAGCAAAACUGUAUAGGAGAGAU
skip 27-5B AUAAAAGCUCCAUACUGAAGAUUUUAUUAGAUUCAUAACA
skip 27-3B CUGUAUAGGAGAGAUUUUGUAUUUUAUUAGAUUCAUAACA
skip 27-3B scram CAAGUAGAUAUUAUAUGUUGUUACUUGUAUAUAUCGAAUG
skip 27-B AUUUUAUUAGAUUCAUAACA
skip 27–53 A1 AUAAAAGCUCCAUACUGAAGCAAAACUGUAUAGGAGAGAUucgaguaugauagggacuuagggug
skip 27–53 mut A1 AUAAAAGCUCCAUACUGAAGCAAAACUGUAUAGGAGAGAUucgaguaugauacgcacuuacgcug
skip 27-3B A1 CUGUAUAGGAGAGAUUUUGUAUUUUAUUAGAUUCAUAACAucgaguaugauagggacuuagggug
skip 27-3B mut A1 CUGUAUAGGAGAGAUUUUGUAUUUUAUUAGAUUCAUAACAucgaguaugauacgcacuuacgcug
skip 27-ex 6–25 UCUUCGAUUUUGUGUGUUCC
skip 27-ex 31–50 UUUAGUCUUAGAGGCUAACG
skip 27-ex 61–80 UGCACUGAAGUCACGGUGUG
skip 27-ex 88–107 UUCAUAUUUGCCAUCUUCUU
skip 27-ex 6–25 scram CUGUUUGUUUCUGACGCUUU
skip 27-ex 31–50 scram CCAUGGGUCUUUUAGUAAAG
skip 27-ex 61–80 scram UGGACAUCGCAGACGUUGGU
skip 27-ex 88–107 scram GUUCUCUUUUUCAUUCCAUA
FLuc A1 GUCUGCUCGAAGCGGCCGGCucgaguaugauagggacuuagggugPage 10 of 13
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The mFold web server [17,61] was used to calculate the
potential secondary structures formed by the APOB exon
27 and adjacent intronic sequences.
Live labeling of HepG2 cells
10 cm plates of HepG2 cells were transfected with the
indicated ASOs at 250 nM for 48 hours. After washing the
cells with 1× PBS + Complete Protease Inhibitors (Roche
Applied Science), the medium was replaced with 4 ml
Dulbecco's Modified Eagle's Medium lacking methionine
and cysteine (Invitrogen) with 0.5 mM oleic acid-1.6%
BSA (Sigma, St Louis, MO). The cells were incubated for
15 min before 200 μCi of Trans-S35-Label (MP Biomedi-
cals, Irvine, CA) was added. The cells were incubated for
60 min, the pulse medium was removed, and the cells
were washed with 1× PBS + Complete Protease Inhibitors.
For the chase, 4 ml of complete DMEM + 1.6% BSA (Inv-
itrogen) was added, and the cells were incubated for 4
hours. Both the pulse and chase media were combined
and subjected to concentration using an Amicon Centri-
con YM-30 (Millipore, Billerica, MA). The cells were
scraped off and lysed in 1 ml modified RIPA (50 mM Tris-
HCl pH 7.4; 0.5% sodium deoxycholate; 150 mM NaCl; 1
mM EDTA, pH 8.0; 1% Triton X-100; 0.1% SDS, 1 mM
PMSF; 1× Complete EDTA-free Protease Inhibitors), then
incubated overnight at 4°C on a rotating mixer. After
microcentrifugation for 5 mins, the cell lysate supernatant
was retained.
The concentrated media were diluted to 12 ml with mod-
ified RIPA. 40 μl of polyclonal anti-APOB (AB742:
Chemicon International, Temecula, CA) was added to the
diluted media and the cell lysate supernatant. After incu-
bation on a rotating mixer for 2 hours at 4°C, 50 μl of a
1:1 slurry of protein A-Sepharose 6 MB in modified RIPA
(GE Healthcare Life Sciences) was added and incubation
was continued for 5 hours. The beads were washed three
times in 1 ml modified RIPA before being boiled with 50
μl 2× SDS-PAGE loading buffer and subjected to SDS-
PAGE on a 4% Tris-glycine gel.
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